Effective omalizumab interval prolongation in the treatment of chronic urticaria

Mehran Alizadeh Aghdam; Rianne Henriëtte Pieterse; Petra Adriana Kentie; Feiko Rijken; André Cornelis Knulst; Heike Röckmann

doi:10.1016/j.jaip.2020.06.056

Effective omalizumab interval prolongation in the treatment of chronic urticaria

Mehran Alizadeh Aghdam^*, Rianne Henriëtte Pieterse, Petra Adriana Kentie, Feiko Rijken, André Cornelis Knulst, Heike Röckmann

^*Corresponding author for this work

Research output: Contribution to journal › Letter › Academic › peer-review

7 Downloads (Pure)

Original language	English
Article number	e1
Pages (from-to)	3667-3668.e1
Journal	Journal of Allergy and Clinical Immunology: In Practice
Volume	8
Issue number	10
DOIs	https://doi.org/10.1016/j.jaip.2020.06.056
Publication status	Published - 1 Nov 2020

Access to Document

10.1016/j.jaip.2020.06.056Licence: CC BY

1-s2.0-S221321982030698X-mainFinal published version, 162 KBLicence: CC BY

Cite this

@article{f89f6891ed324c24bac09d6fb2010320,

title = "Effective omalizumab interval prolongation in the treatment of chronic urticaria",

author = "\{Alizadeh Aghdam\}, Mehran and Pieterse, \{Rianne Henri{\"e}tte\} and Kentie, \{Petra Adriana\} and Feiko Rijken and Knulst, \{Andr{\'e} Cornelis\} and Heike R{\"o}ckmann",

note = "Funding Information: No funding was received for this work. Conflicts of interest: A. C. Knulst is a member of advisory board of Novartis; and has health care innovation grant from Novartis to institution. H. R{\"o}ckmann is a member of national advisory board of Novartis. The rest of the authors declare that they have no relevant conflicts of interest.",

year = "2020",

month = nov,

day = "1",

doi = "10.1016/j.jaip.2020.06.056",

language = "English",

volume = "8",

pages = "3667--3668.e1",

journal = "Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",

publisher = "Elsevier",

number = "10",

}

TY - JOUR

T1 - Effective omalizumab interval prolongation in the treatment of chronic urticaria

AU - Alizadeh Aghdam, Mehran

AU - Pieterse, Rianne Henriëtte

AU - Kentie, Petra Adriana

AU - Rijken, Feiko

AU - Knulst, André Cornelis

AU - Röckmann, Heike

N1 - Funding Information: No funding was received for this work. Conflicts of interest: A. C. Knulst is a member of advisory board of Novartis; and has health care innovation grant from Novartis to institution. H. Röckmann is a member of national advisory board of Novartis. The rest of the authors declare that they have no relevant conflicts of interest.

PY - 2020/11/1

Y1 - 2020/11/1

UR - https://www.scopus.com/pages/publications/85089247783

U2 - 10.1016/j.jaip.2020.06.056

DO - 10.1016/j.jaip.2020.06.056

M3 - Letter

C2 - 32679351

AN - SCOPUS:85089247783

SN - 2213-2198

VL - 8

SP - 3667-3668.e1

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

IS - 10

M1 - e1

ER -

Effective omalizumab interval prolongation in the treatment of chronic urticaria

Access to Document

Other files and links

Cite this